Thymoma-associated MG Immune Cell Growth Tied to Parvovirus B19
An infection with parvovirus B19 may contribute to abnormal immune cell growth in people who have a thymoma, or thymus…
Articles by Marisa Wexler, MS
Depression, Anxiety Reported by 1 in 3 MG Patients, Analysis Shows
More than one in three people with myasthenia gravis (MG) have clinically relevant depression, and a similar proportion have…
CAN106 Gets FDA Orphan Drug Designation for Myasthenia Gravis
CAN106, an investigational complement-inhibiting therapy being developed by CANbridge Pharmaceuticals, has been granted orphan drug designation by the U.S.
Zilucoplan Under Review in US and EU to Treat Generalized MG
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed to review applications seeking the…
High Blood Sugar Levels Prompt MG-driving Immune Cell Activity: Study
The high blood sugar levels that characterize diabetes may prompt immune cells to be activated that can drive and worsen…
Telitacicept Wins Orphan Drug Status to Treat Myasthenia Gravis
Telitacicept (RC18), an anti-inflammatory therapy developed by RemeGen, has been granted orphan drug designation by the U.S. Food and…
NMD670 Shows Signs of Efficacy in Small Phase 1/2a Trial
NMD670 safely improved muscle function and strength in a small clinical trial of people with myasthenia gravis (MG), the…
Experimental Treatment NMD670 Wins FDA Orphan Drug Designation
The U.S. Food and Drug Administration has granted orphan drug status to NMD670, an experimental oral therapy that…
FDA Approval Sought for Under-the-skin Efgartigimod for gMG
Argenx has submitted an application to the U.S. Food and Drug Administration (FDA) requesting the approval of subcutaneous efgartigimod —…
Ultomiris Approved in Japan as Treatment for AChR-Positive gMG
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Ultomiris (ravulizumab) for treating generalized myasthenia gravis (gMG).